Table 1.
Characteristics | CRC (N=32) | GC (N=38) | OC (N=32) |
---|---|---|---|
Age (years) | |||
Median | 57 | 59 | 55 |
Range | 29–79 | 39–80 | 37–75 |
Gender, n(%) | |||
Male | 19(59.4) | 24(63.2) | 0(0) |
Female | 13(40.6) | 14(36.8) | 32(100.0) |
Performance status | |||
(ECOG), n(%) | |||
1 | 7(21.8) | 13(34.2) | 12(37.5) |
2 | 15(46.9) | 21(55.3) | 16(50.0) |
3 | 10(31.3) | 4(10.5) | 4(12.5) |
Tumor histology, n(%) | |||
Adenocarcinoma | 32(100.0) | 38(100.0) | - |
Serous | - | - | 22(81.3) |
Mucinous | - | - | 10(18.7) |
Tumor site, n(%) | |||
Right | 17(53.1) | - | - |
Left | 15(46.9) | - | - |
Tumor stage (TNM), n(%) | |||
III | 11(34.4) | 12(31.6) | 16(50.0) |
IV | 21(65.6) | 26(68.4) | 16(50.0) |
Histologic differentiation | |||
Well | 5(15.6) | 4(10.6) | 4(12.5) |
Moderate | 17(53.1) | 17(44.7) | 18(56.3) |
Poor | 10(31.3) | 17(44.7) | 10(31.2) |
Peritoneal metastasis, n(%) | |||
Positive | 18(56.3) | 22(57.9) | 18(56.3) |
Negative | 14(43.7) | 16(42.1) | 14(43.7) |
Liver metastasis, n(%) | |||
Positive | 16(50.0) | 17(44.7) | 7(21.9) |
Negative | 16(50.0) | 21(55.3) | 25(78.1) |
Ascites volume, n(%) | |||
1500–3000mL | 13(40.6) | 19(50.0) | 14(43.8) |
over 3000 mL | 19(59.4) | 19(50.0) | 18(56.2) |
Diagnosis method of PC(N=58), n(%) | |||
Pathological diagnosis | 5(27.8) | 8(36.4) | 7(38.9) |
CT and tumor cell in ascites | 9(50.0) | 14(63.6) | 6(33.3) |
MRI and tumor cell in ascites | 4(22.2) | 0(0) | 5(27.8) |
Gilly PC (N=58), n(%) | |||
1 | 6(33.3) | 4(18.2) | 2(11.1) |
2 | 4(22.2) | 4(18.2) | 4(22.2) |
3 | 7(38.9) | 10(45.4) | 7(38.9) |
4 | 1(5.6) | 4(18.2) | 5(27.8) |
Treatment received | |||
Prior chemotherapy, n(%) | |||
Yes | 16(50.0) | 24(63.2) | 11(34.4) |
No | 16(50.0) | 14(36.8) | 21(65.6) |
Prior surgery, n(%) | |||
Yes | 15(46.9) | 26(68.4) | 12(37.5) |
No | 17(53.1) | 12(31.6) | 20(62.5) |
Abbreviations: CRC, colorectal cancer; GC, gastric cancer; OC, ovarian cancer.